Table 2. Proportions of each clinical stage, global, and Clinical Dementia Rating Scale – Sum of Boxes from the studies of anti-amyloid drugs that showed clinical benefit.

	Drug		Donanemab	Lecanemab
	Study name		TRAILBLAZER-ALZ 2	CLARITY-AD
Clinical stage (%)		MCI	17.1	61.5
		Mild dementia	82.9	38.5
Global CDR score (%)*		0.5	60.8	80.8
		1.0	36.0	19.2
CDR-SB (max. 18) (mean±sd)*			4.0±2.1	3.2±1.3

Abbreviations: MCI, mild cognitive impairment; CDR-SB, Clinical Dementia Rating – Sum of Boxes Scale; sd, standard deviation.

Note: *obtained from the active treatment group.